| Clinical Feature | HC | MS | MS-Untreated | p-value Untreated vs HC | MS-Treated Alemtuzumab | p-value treated vs HC | p-value untreated vs treated | p-value Chi squared |
| N | 22 | 22 | 12 | - | 10 | - | - | - |
| Age (years)―mean ± SD | 39.4 ± 12.5 | 41.1 ± 15.2 | 46.5 ± 17.0 | 0.444 | 34.7 ± 10.0 | 1.0 | 0.138 | - |
| Gender (female)―N (%) | 6 (73) | 17 (77) | 8 (67) | - | 9 (90) | - | - | 0.426 |
| Gender (male)―N (%) | 16 (27) | 5 (23) | 4 (33) | - | 1 (10) | - | - | |
| Age onset (years)― mean ± SD | - | 32.6 ± 10.7 | 37.2 ± 10.1 | - | 27.2 ± 9.2 | - | 0.004 |
|
| EDSS―mean ± SD | - | 2.4 ± 2.6 | 1.8 ± 2.3 | - | 3±2.9 | - | 0.434 |
|
| Total number of relapses―mean ± SD | - | 3.4 ± 2.7 | 3.4 ± 3.3 | - | 3.3 ± 1.9 | - | 0.833 |
|